400 related articles for article (PubMed ID: 16585217)
41. Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and
Orozco JJ; Kenoyer AL; Lin Y; O'Steen S; Guel R; Nartea ME; Hernandez AH; Hylarides MD; Fisher DR; Balkin ER; Hamlin DK; Wilbur DS; Orcutt KD; Wittrup KD; Green DJ; Gopal AK; Till BG; Sandmaier B; Press OW; Pagel JM
Mol Cancer Ther; 2020 Dec; 19(12):2575-2584. PubMed ID: 33082277
[TBL] [Abstract][Full Text] [Related]
42. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
43. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Knox SJ; Goris ML; Tempero M; Weiden PL; Gentner L; Breitz H; Adams GP; Axworthy D; Gaffigan S; Bryan K; Fisher DR; Colcher D; Horak ID; Weiner LM
Clin Cancer Res; 2000 Feb; 6(2):406-14. PubMed ID: 10690517
[TBL] [Abstract][Full Text] [Related]
44. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
Pagel JM; Orgun N; Hamlin DK; Wilbur DS; Gooley TA; Gopal AK; Park SI; Green DJ; Lin Y; Press OW
Blood; 2009 May; 113(20):4903-13. PubMed ID: 19124831
[TBL] [Abstract][Full Text] [Related]
45. Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.
Green DJ; Frayo SL; Lin Y; Hamlin DK; Fisher DR; Frost SH; Kenoyer AL; Hylarides MD; Gopal AK; Gooley TA; Orozco JJ; Till BG; O'Steen S; Orcutt KD; Wilbur DS; Wittrup KD; Press OW
Cancer Res; 2016 Nov; 76(22):6669-6679. PubMed ID: 27590740
[TBL] [Abstract][Full Text] [Related]
46. Applying biotin-streptavidin binding for iscom (immunostimulating complex) association of recombinant immunogens.
Wikman M; Friedman M; Pinitkiatisakul S; Hemphill A; Lövgren-Bengtsson K; Lundén A; Ståhl S
Biotechnol Appl Biochem; 2005 Apr; 41(Pt 2):163-74. PubMed ID: 15296488
[TBL] [Abstract][Full Text] [Related]
47. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen.
Rheinnecker M; Hardt C; Ilag LL; Kufer P; Gruber R; Hoess A; Lupas A; Rottenberger C; Plückthun A; Pack P
J Immunol; 1996 Oct; 157(7):2989-97. PubMed ID: 8816407
[TBL] [Abstract][Full Text] [Related]
48. Design of a bifunctional fusion protein for ovarian cancer drug delivery: single-chain anti-CA125 core-streptavidin fusion protein.
Wang WW; Das D; McQuarrie SA; Suresh MR
Eur J Pharm Biopharm; 2007 Mar; 65(3):398-405. PubMed ID: 17257818
[TBL] [Abstract][Full Text] [Related]
49. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
50. Production and characterization of an active single-chain variable fragment antibody recognizing CD25.
Muramatsu H; Yoshikawa K; Hayashi T; Takasu S; Kawada Y; Uchida K; Sato S; Takahashi T; Saga S; Ueda R
Cancer Lett; 2005 Jul; 225(2):225-36. PubMed ID: 15978327
[TBL] [Abstract][Full Text] [Related]
51. [Construction and expression of an anti-GD2,ScFv-IL-2 fusion protein gene].
Ni J; Ji J; Lü A; Huang R; Wei Y; Wu W
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Feb; 24(1):170-5. PubMed ID: 17333916
[TBL] [Abstract][Full Text] [Related]
52. Generation of a single-chain Fv fragment for the monitoring of deoxycholic acid residues anchored on endogenous proteins.
Kobayashi N; Ohtoyo M; Wada E; Kato Y; Mano N; Goto J
Steroids; 2005 Apr; 70(4):285-94. PubMed ID: 15784283
[TBL] [Abstract][Full Text] [Related]
53. Anti-estradiol-17beta single-chain Fv fragments: Generation, characterization, gene randomization, and optimized phage display.
Kobayashi N; Kato Y; Oyama H; Taga S; Niwa T; Sun P; Ohtoyo M; Goto J
Steroids; 2008 Dec; 73(14):1485-99. PubMed ID: 18824188
[TBL] [Abstract][Full Text] [Related]
54. Cloning, expression, and characterization of single-chain variable fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli.
Choi GH; Lee DH; Min WK; Cho YJ; Kweon DH; Son DH; Park K; Seo JH
Protein Expr Purif; 2004 May; 35(1):84-92. PubMed ID: 15039070
[TBL] [Abstract][Full Text] [Related]
55. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
56. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
[TBL] [Abstract][Full Text] [Related]
57. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
[TBL] [Abstract][Full Text] [Related]
58. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
59. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
60. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
